Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817889 · ClinicalTrials.gov registry record · Phase 2
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
A Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Autoimmune Disease, sponsored by Fred Hutchinson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT06817889 is a Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Autoimmune Disease that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 60 participants, below the 482-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06817889, a Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Autoimmune Disease, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
- DRUG Remdesivir
- PROCEDURE Nasal Swab
Study Locations (3)
California
- City of Hope Comprehensive Cancer Center - Duarte
Texas
- MD Anderson Cancer Center - Houston
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-23 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06817889
The ClinicalTrials.gov registry entry for NCT06817889 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (88% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06817889 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT06817889 about?
NCT06817889 is a clinical study titled "Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals". This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infe...
What is the current status of trial NCT06817889?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-23. Estimated completion is 2027-11-30.
What conditions does trial NCT06817889 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection.
What interventions are being tested in trial NCT06817889?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Remdesivir (DRUG), Nasal Swab (PROCEDURE).
Who is sponsoring clinical trial NCT06817889?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817889 being conducted?
This trial has 3 study locations across California, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphatic System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
RECRUITING · Phase 2
-
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Hematopoietic and Lymphatic System Neoplasm
All registered trials for this condition
Autoimmune Disease
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.